1. Sun, Qian, Xu, Junjie, Yuan, Fan'en, Dong, Huimin, Liu, Baohui. 2024. RND1 inhibits epithelial-mesenchymal transition and temozolomide resistance of glioblastoma via AKT/GSK3-β pathway. In Cancer biology & therapy, 25, 2321770. doi:10.1080/15384047.2024.2321770. https://pubmed.ncbi.nlm.nih.gov/38444223/
2. Komatsu, Hisateru, Iguchi, Tomohiro, Masuda, Takaaki, Mori, Masaki, Mimori, Koshi. 2016. Attenuated RND1 Expression Confers Malignant Phenotype and Predicts Poor Prognosis in Hepatocellular Carcinoma. In Annals of surgical oncology, 24, 850-859. doi:10.1245/s10434-016-5573-9. https://pubmed.ncbi.nlm.nih.gov/27770342/
3. Kluge, Annika, Rangrez, Ashraf Yusuf, Kilian, Lucia Sophie, Frey, Norbert, Frank, Derk. 2019. Rho-family GTPase 1 (Rnd1) is a biomechanical stress-sensitive activator of cardiomyocyte hypertrophy. In Journal of molecular and cellular cardiology, 129, 130-143. doi:10.1016/j.yjmcc.2019.01.028. https://pubmed.ncbi.nlm.nih.gov/30797814/
4. Mouly, Laetitia, Mamouni, Kenza, Gence, Remi, Sordet, Olivier, Monferran, Sylvie. 2018. PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin. In Cell death & disease, 9, 931. doi:10.1038/s41419-018-0981-3. https://pubmed.ncbi.nlm.nih.gov/30209297/
5. Qin, Cheng-Dong, Ma, De-Ning, Zhang, Shi-Zhe, Sun, Hui-Chuan, Tang, Zhao-You. 2018. The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target. In Cell death & disease, 9, 486. doi:10.1038/s41419-018-0517-x. https://pubmed.ncbi.nlm.nih.gov/29706627/
智鼠故事 
